Stephen Mark Tompkins

Summary

Affiliation: University of Georgia
Country: USA

Publications

  1. ncbi Protection against lethal influenza virus challenge by RNA interference in vivo
    Stephen Mark Tompkins
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:8682-6. 2004
  2. ncbi Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007

Detail Information

Publications2

  1. ncbi Protection against lethal influenza virus challenge by RNA interference in vivo
    Stephen Mark Tompkins
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:8682-6. 2004
    ..These results indicate that RNA interference is promising for control of influenza virus infection, as well as other viral infections...
  2. ncbi Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A...